NDAINTRAVENOUSSOLUTION
Approved
Feb 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ACETAMINOPHEN (acetaminophen) by B. Braun is 12. First approved in 2021.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Acetaminophen is a generic analgesic and antipyretic agent available as an intravenous solution formulation marketed by B. Braun. It reduces pain and fever through central nervous system mechanisms, though the precise mechanism remains incompletely understood. The IV formulation achieves higher peak concentrations than oral dosing while maintaining similar overall systemic exposure.
Peak
Peak lifecycle status indicates mature market position with established commercial infrastructure, though limited Part D data suggests modest commercial investment relative to OTC acetaminophen dominance.
Mechanism of Action
12.1 Mechanism of Action The precise mechanism of the analgesic and antipyretic properties of acetaminophen is not established but is thought to primarily involve central actions. 12.2 Pharmacodynamics Acetaminophen has been shown to have analgesic and antipyretic activities in animal and human…
Worked on ACETAMINOPHEN at B. Braun? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.